Discovery and clinical development of dutasteride, a potent dual 5α-reductase inhibitor

Current Topics in Medicinal Chemistry

Volumn 6, Issue 5, 2006, Pages 405-421

  Frye, Stephen V ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

5AR isozymes; Dihydrofinasteride NADP adduct; Progesterone; Prostate cDNA library; Vermeulen

Indexed keywords

ANDROSTANOLONE; DUTASTERIDE; FINASTERIDE; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE INHIBITOR;

CANCER RISK; CLINICAL TRIAL; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG RESEARCH; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; EJACULATION DISORDER; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; HIGH RISK POPULATION; HUMAN; IMPOTENCE; LIBIDO DISORDER; MALE; MALE SEXUAL DYSFUNCTION; NONHUMAN; PROSTATE CANCER; PROSTATE HYPERTROPHY; REVIEW; RISK REDUCTION; STRUCTURE ACTIVITY RELATION;

ANIMALS; AZASTEROIDS; CHOLESTENONE 5 ALPHA-REDUCTASE; CLINICAL TRIALS, PHASE III; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; HUMANS; MALE; MOLECULAR CONFORMATION; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33646127626     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802606776743101     Document Type: Review

References (87)

1. Isaacs, J.T. Importance of the Natural History of Benign Prostatic Hyperplasia in the Evaluation of Pharmacologic Intervention. Prostate Suppl., 1990, 3, 1-7.
2. Geller, J. Benign Prostatic Hyperplasia: Pathogenesis and Medical Therapy. J. Am. Geriat. Soc., 1991, 39, 1208-1216.
3. Jemal, A.; Murray, T.; Ward, E.; Samuels, A.; Tiwari, R. C.; Ghafoor, A.; Feuer, E. J.; Thun, M. J. Cancer Statistics, 2005. CA: a Cancer Journal for Clinicians, 2005, 55, 10-30.
4. Lee, K. L.; Peehl, D. M. Molecular Pathogenesis of Benign Prostatic Hyperplasia. J. Urol., 2004, 172, 1784-1791.
5. Moore, R.A. Benign Hypertrophy and Carcinoma of the Prostate, Occurrence and Experimental Production in Animals. Surgery, 1944, 16, 152.
6. Imperato-McGinley, J.; Guerrero, L.; Gautier, T.; Peterson, R.E. Steroid 5α-Reductase Deficiency in Man: an Inherited Form of Male Pseudohermaphroditism. Science, 1974, 186, 1213-1215.
7. Griffiths, K.; Eaton, C.L.; Harper, M.E.; Peeling, B.; and Davies, P. Steroid Hormones and the Pathogenesis of Benign Prostatic Hyperplasia, Eur. Urol., 1991, 20, 68-77.
8. Kreig, M.; Nass, R.; Tunn, S. Effect of Aging on Endogenous Level of 5α-Dihydrotestosterone, Testosterone, Estradiol, and Estrone in Epithelium and Stroma of Normal and Hyperplastic Human Prostate. J. Clin. Endocrinol. Metab., 1993, 77, 375-381.
9. Petrow, V.; Padilla, G.M. 5α-Reductase: a Target Enzyme for Prostatic Cancer. In Novel Approaches Cancer Chemother.; Sunkara; P. S. Ed.; Academic, Orlando, 1984; pp. 269-305.
10. Gormley, G.J. Role of 5α-Reductase Inhibitors in the Treatment of Advanced Prostatic Carcinoma, Urol. Clin. N. Amer., 1991, 18, 93-98.
11. Presti, J.C.; Fair, W.R.; Andriole, G.; Sogani, P.C.; Seidmon, E.J.; Ferguson, D.; Ng, J.; Gormley, G.J. Multicenter, Randomized, Double-blind, Placebo Controlled Study to Investigate the Effect of Finasteride (MK-906) on Stage D Prostate Cancer. J. Urol., 1992, 148, 1201-1204.
12. Thompson, I. M.; Goodman, P. J.; Tangen, C. M.; Lucia, M. S.; Miller, G. J.; Ford, L. G.; et al. The Influence of Finasteride on the Development of Prostate Cancer. N. Engl. J. Med., 2003, 349, 215-224.
13. Tenover, J.S. Prostates, Pates and Pimples: The Potential Medical Uses of Steroid 5α-Reductase Inhibitors. Endocrinol. Metab. Clin. N. Amer., 1991, 20, 893-909.
14. Libecco, J. F.; Bergfeld, W. F. Finasteride in the Treatment of Alopecia. Expt. Op. Pharmacotherapy, 2004, 5, 933-940.
15. Russell, D.W.; Wilson, J.D. Steroid 5α-Reductase: Two genes/ Two Enzymes. Annu. Rev. Biochem., 1994, 63, 25-61.
16. Josso, N. Anatomy and Endocrinology of Fetal Sex Differentiation. In Endocrinology, Volume 2; L. J. DeGroot, Ed.; W.B. Saunders: Philadelphia, 1994; pp. 1888-1900.
17. Wilson, J.D. Sexual Differentiation of the Gonads and of the Reproductive Tract. Biol. Neonate, 1989, 55, 322-330.
18. Walsh, P.C.; Madden, J.D.; Harrod. M.J.; Goldstein, J.L.; MacDonald, P.C.; Wilson, J.D. Familial Incomplete Male Pseudohermaphroditism, Type 2. Decreased Dihydro-testosterone Formation in Pseudovaginal Perineoscrotal Hypospadias. N. Engl. J. Med., 1974, 291, 944-949.
19. Andersson, S.; Berman, D. M.; Jenkins, E. P.; Russell, D. W. Deletion of Steroid Sα-Reductase 2 Gene in Male Pseudohermaphroditism. Nature, 1991, 354, 159-161.
20. Thigpen, A.E.; Davis, D.L.; Milatovich, A.; Mendonca, B.B.; Imperato-McGinley, J.; Griffin, J.E.; Francke, U.; Wilson, J.D.; Russell, D.W. Molecular Genetics of Steroid 5α-Reductase 2 Deficiency, J. Clin. Invest., 1992, 90, 799-809.
21. Imperato-McGinley, J.; Gautier, T.; Zirinsky, K.; Hom, T.; Palomo, O.; Stein, E.; Vaughan, E.D.; Markisz, J.A.; Arellano, E. R.; Kazam, E. Prostate Visualization Studies in Males Homozygous and Heterozygous for 5α-Reductase Deficiency. J. Clin. Endocrinol. Metab., 1992, 75, 1022-1026.
22. Imperato-McGinley J.; Gautier, T.; Cai, L-Q.; Yee, B.; Epstein, J.; Pochi, P. The Androgen Control of Sebum Production: Studies of Subjects with Dihydrotestosterone Deficiency and Complete Androgen Insensitivity. J. Clin. Endocrinol. Metab., 1993, 76, 524-528.
23. Martini, L. The 5α-Reduction of Testosterone in the Neuroendocrine Structures: Biochemical and Physiological Implications. Endocrine Rev., 1982, 3, 1-25.
24. Martini, L.; Melcangi, R.C. Androgen Metabolism in the Brain. J Steroid Biochem. Molec. Biol., 1991, 39, 819-828.
25. Melcangi, R.C.; Celotti, F.; Martini, L. Progesterone 5-α-Reduction in Neuronal and in Different types of Glial Cell Culture: Type 1 and 2 Astrocytes and Oligodendrocytes. Brain Res., 1994, 639, 202-206.
26. Andersson, S.; Bishop, R.W.; Russell, D.W. Expression Cloning and Regulation of Steroid 5α-Reductase, An Enzyme Essential for Male Sexual Differentiation. J. Biol. Chem., 1989, 264, 16249-16255.
27. Levine, A.C.; Wang, J-P.; Ren, M.; Eliashvilli, E.; Russell, D.W.; Kirschenbaum, A. Immunohistochemical Localization of Steroid 5α-Reductase 2 in Human Male Fetal Reproductive Tract and Adult Prostate. J. Clin. Endocrinol. Metab., 1996, 81, 384-389.
28. Bruchovsky, N.; Sadar, M. D.; Akakura, K. Goldenberg, S. L.; Matsuoka, K.; Rennie, P. S. Characterization of 5alpha-Reductase Gene Expression in Stroma and Epithelium of Human Prostate. J. Steroid Biochem. Mol. Biol., 1996, 59, 397-404.
29. Thigpen, A. E.; Silver, R. I.; Guileyardo, J. M.; Casey, M. L.; McConnell, J. D.; Russell, D. W. Tissue Distribution and Ontogeny of Steroid 5α-Reductase Isozyme Expression. J. Clin. Invest., 1993, 92, 903-910.
30. Thomas, L. N.; Douglas, R. C.; Vessey, J. P.; Gupta, R.; Fontaine, D.; Norman, R. W. et al. 5-α Reductase Type 1 Immunostaining is Enhanced in Some Prostate Cancers Compared with Benign Prostatic Hyperplasia Epithelium. J. Urol., 2003, 170, 2019-2025.
31. Tian, G.; Stuart, J. D.; Moss, M. L.; Domanico, P. L.; Bramson, H. N.; Patel, I. R.; Kadwell, S. H.; Overton, L. K.; Kost, T. A.; Mook, Jr. R. A.; Frye, S. V.; Batchelor, K. W.; Wiseman, J. S. 17β-(N-tert-butylcarbamoyl)-4-aza-5α-androstan-1-en-3-one is an Active Site-Directed Slow Time-Dependent Inhibitor of Human Steroid 5-Alpha-Reductase. Biochemistry, 1994, 33, 2291-2296.
32. Levy, M.A.; Brandt, M.; Greway, A.T. Mechanistic Studies with Solubilized Rat Liver Steroid 5α-Reductase: Elucidation of the Kinetic Mechanism. Biochemistry, 1990, 29, 2808-2815.
33. Frye, S.V. Inhibitors of 5α-Reductase. Current Pharm. Design, 1996, 2, 59-84.
34. Liang, T.; Heiss, C.E. Inhibition of 5α-Reductase, Receptor Binding, and Nuclear Uptake of Androgens in the Prostate by a 4-Methyl-4-aza-steroid. J. Biol. Chem., 1981, 256, 7998-8005.
35. Cooke, G.M.; Robaire, B. J. The Effects of Diethyl-4-methyl-3-oxo-4-aza-5α-androstane-17β-carboxamide (4MA) and (4R)-5,10-Seco-19-norpregna-4,5-diene-3,10,20-trione (SECO) on Androgen Biosynthesis in the Rat Testis and Epididymis. Steroid Biochem., 1986, 24, 877-886.
36. Chan, W.K.; Fong, C.Y.; Tiong, H.H.; Tan, C.H. The Inhibition of 3bHSD Activity in Porcine Granulosa Cells by 4-MA, a Potent 5α-Reductase Inhibitor. Biochem. Biophys. Res. Comm., 1987, 144, 166-171.
37. 5-steroid Isomerase from Bovine Adrenals: Mechanism of Inhibition by 3-Oxa-4-aza Steroids and Kinetic Mechanism of the Dehydrogenase. Biochemistry, 1989, 28, 140-148.
38. 4 - isomerase Activity in Guinea Pig Adrenals. Steroids, 1994, 59, 371-376.
39. 5 -steroid Isomerase. J. Med. Chem., 1994, 37, 2352-2360.
40. McConnell, J.D. Androgen Ablation and Blockade in the Treatment of Benign Prostatic Hyperplasia. Urolog. Cin. N. Amer., 1990, 17, 661-670.
41. Rasmusson, G.H.; Reynolds, G.F.; Utne, T.; Jobson, R.B.; Primka, R.L.; Berman, C.; Brooks, J.R. Azasteroids as Inhibitors of Rat Prostatic 5α-Reductase. J. Med. Chem., 1984, 27, 1690-1701.
42. Rasmusson, G.H.; Reynolds, G.F.; Steinberg, N.G.; Walton, E.; Patel, G.F.; Liang, T.; Cascieri, M.A.; Cheung, A.H.; Brooks, J.R.; Berman, C. Azasteroids: Structure-activity Relationships for Inhibition of 5α-Reductase and of Androgen Receptor Binding. J Med. Chem., 1986, 29, 2298-2314.
43. Rittmaster, R.S. Finasteride. New Engl. J. Med., 1994, 330, 120-125.
44. Vermeulen, A.; Giagulli, V. A.; De Schepper, P.; Buntinx, A.; Stoner, E. Hormonal Effects of an Orally Active 4-Azasteroid Inhibitor of 5α-Reductase in Humans. The Prostate, 1989, 14, 45-53.
45. Gormley, G. L.; Stoner, E.; Rittmaster, R. S.; Gregg, H.; Thompson, D. L.; Lasseter, K. C.; Vlasses, P. H.; Stein, E. A. Effects of Finasteride (MK-906), a 5α-Reductase Inhibitor, on Circulating Androgens in Male Volunteers. J. Clin. Endocrinol. Metab., 1990, 70, 1136-1141.
46. Ohtawa M.; Morikawa H.; Shimazaki J. Pharmacokinetics and Biochemical Efficacy After Single and Multiple Oral Administration of N-(2-Methyl-2-propyl)-3-oxo-4- aza-5α-androst-1-ene-17β-carboxamide, a New Type of Specific Competitive Inhibitor of Testosterone 5α-Reductase, in Volunteers. Eur. J. Drug Metab. Pharmacokin., 1991, 16, 15-21.
47. Vermeulen, A.; Giagulli, V. A.; De Schepper, P. J.; Buntinx, A. Hormonal Effects of a 5α-Reductase Inhibitor (finasteride) on Hormonal Levels in Normal Men and in Patients with Benign Prostatic Hyperplasia. Eur. Urol., 1991, 20, 82-86.
48. De Schepper, P. J.; Imperoto-McGinley, J.; Van Hecken, A.; De Lepeleire, I.; Buntinx, A.; Carlin, J.; Gressi, M. H.; Stoner, E. Hormonal Effects, Tolerability, and Preliminary Kinetics in Men of MK-906, a 5α-Reductase Inhibitor. Steroids, 1991, 56, 469-471.
49. Finasteride package insert, Merck Inc.
50. Mocellini, A. I.; Gardiner, R.; Marshall, V.; Johnson, W.; Bartsch, G.; Schmidbauer; C. P.; et al. Finasteride (MK-906) in the Treatment of Benign Prostatic Hyperplasia. The Prostate, 1993, 22, 291-299.
51. Stoner, E. Maintenance of Clinical Efficacy with Finasteride Therapy for 24 Months in Patients with Benign Prostatic Hyperplasia. Arch. Intern. Med., 1994, 154, 83-88.
52. Faller, B.; Farley, D.; Nick, H. Finasteride: A Slow-binding 5α-Reductase Inhibitor. Biochemistry, 1993, 32, 5705-5710.
53. 1-4-Azasteroids: Toward Perfection of Rates of Time-dependent Inhibition by Using Ligand-binding Energies. Biochemistry, 1995, 34, 13453-13459.
54. Tian, G.J. In vivo Time-dependent Inhibition of Human Steroid 5α-Reductase by Finasteride. Pharmaceut. Sci., 1996, 85, 106-111.
55. Bull, H. G.; Garcia-Calvo, M.; Anderson, S.; Baginsky, W. F.; Chan, H. K.; Ellsworth, D. E.; et al. Mechanism-based Inhibition of Human Steroid 5α-Reductase by Finasteride: Enzyme-catalyzed Formation of NADP-Dihydrofinasteride, a Potent Bisubstrate Analog Inhibitor. J. Am. Chem. Soc., 1996, 118, 2359-2365.
56. Shapiro, E.; Becich, M.J.; Hartanto, V.; Lepor, H. The Relative Proportion of Stromal and Epithelial Hyperplasia is Related to the Development of Symptomatic Benign Prostatic Hyperplasia. J. Urol., 1992, 147, 1293-1297.
57. Barry, M.J.; Cockett, A.T.K.; Holtgrewe, H.L.; McConnell, J.D.; Sihelnik, S.A.; Winfield, H.N. Relationship of Symptoms of Prostatism to Commonly Used Physiological and Anatomical Measures of the Severity of Benign Prostatic Hyperplasia. J. Urol., 1993, 150, 351-358.
58. Grino, P.B.; Griffin, J.E., Wilson, J.D. Testosterone at High Concentrations Interacts with the Human Androgen Receptor Similarly to Dihydrotestosterone. Endocrinology, 1990, 126, 1165-1172.
59. Liang, T.; Cascieri, M. A.; Cheung, A. H.; Reynolds, G. F.; Rasmusson, G. H. Species Differences in Prostatic Steroid 5α-Reductases of Rat, Dog, and Human. Endocrinology, 1985, 117, 571-579.
60. Jenkins, E. P.; Anderson, S.; Imperato-McGinley, J.; Wilson, J. D.; Russell, D. W. Genetic and Pharmacological Evidence for More Than One Human Steroid 5α-Reductase. J. Clin. Invest., 1992, 89, 293-300.
61. Andersson, S.; Russell, D. W. Structural and Biochemical Properties of Cloned and Expressed Human and Rat Steroid 5α-Reductases. Proc. Natl. Acad. Sci. USA, 1990, 87, 3640-3644.
62. Tian, G.; Chen, S.-Y.; Facchine, K. L.; Prakash, S. R. Chemical Mechanism of the Covalent Modification of 5α-Reductases by Finasteride as Probed by Secondary Tritium Isotope Effects. J. Am. Chem. Soc., 1995, 117, 2369-2370.
63. Frye, S. V.; Bramson, H. N.; Hermann, D. J.; Lee, F. W.; Sinhababu, A. K.; Tian, G. Discovery and development of GG745, a potent inhibitor of both isoenzymes of 5α-reductase. In Integration of Pharmaceutical Discovery and Development; Borchardt et al.; Eds.; Plenum Press: New York, 1998; pp. 393-422.
64. Wolfenden, R. Analog Approaches to the Structures of the Transition State in Enzyme Reactions. Acc. Chem. Res., 1972, 5, 10-18.
65. Lettré, H.; Knof, L. 6-Aza-Cholesterol and Derivatives. Chem. Ber., 1960, 93, 2860-2864.
66. Frye, S. V.; Haffner, C. D.; Maloney, P. R.; Mook Jr. R. A.; Dorsey Jr. G. F., Hiner, R. N., Batchelor, K. W.; et al. 6-Azasteroids: Potent Dual Inhibitors of Human Type 1 and 2 Steroid 5α-Reductase. J. Med. Chem., 1993, 36, 4313-4315.
67. 5-steroid Isomerase by 6-Azaandrost-4-en-3-ones: Optimization of the C17 Substituent. J. Med Chem., 1995, 38, 2621-2627.
68. Tippin T. K.; Sinhababu, A. K.; Lee. F. W.; Haffner, C.; Maloney, P.; Hiner, R.; Frye, S. V. Application of Microsomal Metabolism Rates to Identify 6-Azasteroidal 5α-Reductase Inhibitors with Optimum in vivo Half-life, ISSX Proceedings, 1995, 8, 46.
69. Carlin, J. R.; Christofalo, P.; Arison, B.H.; VandenHeuvel, W. J. A.; Miller, R. R.; Ellsworth, R. L.; Chiu, S.-H. L. The Disposition and Pharmacokinetics of Finasteride in the Dog. ISSX Proc., 1992, 2, 197.
70. 14C]-Finasteride After Oral Administration in Humans. Drug Metab. Dispos., 1992, 20, 148-155.
71. Bakshi, R. K.; Rasmusson, G.H.; Patel, G.F.; Mosley, R.T.; Chang, B.; Ellsworth, K.; Harris, G.S.; Tolman, R.L. 4-Aza-3-oxo-5α-androst-1-ene-17β-N-aryl-carboxamides as Dual inhibitors of Human Type 1 and 2 Steroid 5α-Reductases. Dramatic Effect of N-Aryl Substituents on Type 1 and Type 2 5α-Reductase Inhibitory Potency. J. Med. Chem., 1995, 38, 3189-3192.
72. Stuart, J. D.; Lee, F. W.; Simpson N. D.; Kadwell, S. H.; Overton, L. K.; Hoffman, C. R.; Kost, T. A.; Tippin, T. K.; Yeager, R. L.; Batchelor, K. W.; Bramson, H. N. Pharmacokinetic Parameters and Mechanisms of Inhibition of Rat Type 1 and 2 Steroid 5alpha-reductases: Determinants for Different in vivo Activities of G1198745 and Finasteride in the Rat. Biochem. Pharm., 2001, 62, 933-42.
73. Lipinski, C. A. Lead- and Drug-like Compounds: the Rule-of-five Revolution. Drug Discov. Today: Technologies, 2004, 1, 337-341.
74. Dutasteride package insert, GlaxoSmithKline Inc.
75. Morris, D. M.; Grosse, C. M.; Selinger, K. A.; Determination of G1198745 in Human Serum by LC/APCI/MS, Abstract, The 6th International Symposium for Pharmaceutical and Biomedical Analysis, 1995, St. Louis, M-P/A9.
76. Clark, R. V.; Hermann, D. J.; Cunningham, G. R.; Wilson, T. H.; Morrill, B. B.; Hobbs, S. Marked Suppression of Dihydrotestosterone in Men with Benign Prostatic Hyperplasia by Dutasteride, a Dual 5alpha-Reductase Inhibitor. J. Clin. Endocrinol. Metab., 2004, 89, 2179-84.
77. Andriole, G. L.; Humphrey, P.; Ray, P.; Gleave, M. E.; Trachtenberg, J.; Thomas, L. N.; Lazier, C. B.; Rittmaster, R. S. Effect of the Dual 5α-Reductase Inhibitor Dutasteride on Markers of Tumor Regression in Prostate Cancer. J. Urol., 2004, 172, 915-919.
78. McConnell, J. D.; Wilson, J. D.; George, F. W.; Geller, J.; Pappas, F.; Stoner, E. Finasteride, an Inhibitor of 5alpha-Reductase, Suppresses Prostatic Dihydrotestosterone in Men with Benign Prostatic Hyperplasia. J. Clin. Endocrinol. Metab., 1992, 74, 505-8.
79. Span, P. N.; Voller, Maureen, C. W.; Smals, A. G. H.; Sweep, F. G. J.; Schalken, J. A.; Feneley, M. R.; Kirby, R. S. Selectivity of Finasteride as an in vivo Inhibitor of 5α-Reductase Isoenzyme Enzymic Activity in the Human Prostate. J. Urol., 1999, 161, 332-337.
80. Roehrborn, C. G.; Boyle, P.; Bergner, D.; Gray, T.; Gittelman, M.; Shown, T.; Melman, A.; Bracken, R. B.; deVere White, R.; Taylor, A.; Wang, D.; Waldstreicher, J. Serum Prostate-specific Antigen and Prostate Volume Predict Long-term Changes in Symptoms and Flow Rate: Results of a Four-Year, Randomized Trial Comparing Finasteride Versus Placebo. PLESS Study Group. Urology, 1999, 54, 662-9.
81. Roehrborn, C. G.; Boyle, P.; Nickel, J. C.; Hoefner, K.; Andriole, G. Efficacy and Safety of a Dual Inhibitor of 5-alpha-Reductase Types 1 and 2 (Dutasteride) in Men with Benign Prostatic Hyperplasia. Urology, 2002, 60, 434-41.
82. Roehrborn, C. G.; Marks, L. S.; Fenter, T.; Freedman, S.; Tuttle, J.; Gittleman, M.; Morrill, B.; Wolford, E. T. Efficacy and Safety of Dutasteride in the Four-year Treatment of Men with Benign Prostatic Hyperplasia. Urology, 2004, 63, 709-15.
83. Andriole, G.; Bostwick, D.; Brawley, O.; Gomella, L.; Marberger, M.; Tindall, D.; Breed, S.; Somerville, M.; Rittmaster, R. Chemoprevention of Prostate Cancer in Men at High Risk: Rational and Design of the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) Trial. J. Urol., 2004, 172, 1314-1317.
84. Iehle, C.; Radvanyi, F.; Gil Diez de Medina, S.; Ouafik, L.H.; Gerard, H.; Chopin, D.; Raynaud, J-P.; Martin, P-M. Differences in Steroid 5α-Reductase Isoenzymes Expression Between Normal and Pathological Human Prostate Tissue. J. Steroid Biochem. Mol. Biol., 1999, 68, 189-195.
85. Bonkhoff, H.; Stein, U.; Aumuller, G.; Remberger, K. Differential Expression of 5alpha-Reductase Isoenzymes in the Human Prostate and Prostatic Carcinomas. Prostate, 1996, 29, 261-7.
86. Thomas, L.N.; Douglas, R.C.; Gupta, R.; Norman, R.W.; Lazier, C.B.; Rittmaster, R.S. Differential Alterations in 5α-reductase Type 1 and Type 2 Levels During Development and Progression of Prostate Cancer. Prostate, 2005, 63, 231-9.
87. Robertson, J. G. Mechanistic Basis of Enzyme-Targeted Drugs, Biochemistry, 2005, 44, 5561-5571.